Aurora Spine, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$5.7Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
73clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Zip $2.4M associated (2023-2025)
- Discovery Tinano Acif $721K associated (2023-2025)
- Aurora Spine $105K associated (2023-2025)
- Apollo Anterior Cervical Plate System $51K associated (2023-2025)
- Silo Tfx $19K associated (2023-2025)
- Silo Tfx Mis Sacroiliac Joint Fixation System $17K associated (2023-2025)
- Mega Plus Mis Spine System $5,000 associated (2023-2025)
- Tinano $2,778 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Steven Falowski | Fountain Hill, PA | Neurological Surgery | $623,253.85 |
| Daniel Barba | Escondido, CA | Orthopaedic Surgery of The Spine | $613,447.23 |
| Tiffany Rogers | Torrance, CA | Orthopaedic Surgery | $538,771.19 |
| Sebastian Koga | Hammond, LA | Neurological Surgery | $500,017.67 |
| Vipul Mangal | Oxon Hill, MD | Pain Medicine (Anesthesiology) | $398,313.49 |
| Steven Anagnost | Tulsa, OK | Orthopaedic Surgery of The Spine | $387,232.43 |
| Pankaj Mehta | Killeen, TX | Interventional Pain Medicine | $324,131.17 |
| Michael Stoffman | Niagara Falls, NY | Neurological Surgery | $274,045.72 |
| Anish Patel | Frederick, MD | Interventional Pain Medicine | $242,296.00 |
| Jason Pope | Santa Rosa, CA | Pain Medicine (Anesthesiology) | $238,427.81 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.